Meta AnalysisID 2740
使用质子泵抑制剂或组胺-2受体拮抗剂的儿童患社区获得性肺炎的风险：系统评价
CRD42018093606
P Children, aged 1 month until 18 years. I/E Proton-pump inhibitor or histamine-2 receptor antagonist. C No proton-pump inhibitors or histamine-2 receptor antagonist. O Community-acquired pneumonia (or (lower)
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2740
- Evidence Id
- 11298
- Core Evidence Id
- 11298
- Source Meta Analysis Id
- 2690
- Herb2 Meta Analysis Id
- HBMA002690
- Crd Id
- CRD42018093606
- Title
- The risk of community-acquired pneumonia in children using proton pump inhibitors or histamine-2 receptor antagonists: a systematic review<br />
- Review Question
- P Children, aged 1 month until 18 years. I/E Proton-pump inhibitor or histamine-2 receptor antagonist. C No proton-pump inhibitors or histamine-2 receptor antagonist. O Community-acquired pneumonia (or (lower) respiratory tract infections)
- Study Type Included
- As it is expected that there will be a relatively small number of studies eligible for inclusion, we will include all study designs in which primary data were collected. In reporting the evidence, we will use the best available evidence to answer our research question, taking the following hierarchy of evidence in to consideration: randomized controlled trials (RCTs), controlled (non-randomized) clinical trials (CCTs), cohort studies, case-control studies, case series with historical control group, case series without historical control group and case reports. If there is sufficient evidence to answer our objective, evidence of lower hierarchy will no longer be included. We will not use a language restriction and seek translation for abstracts and full texts published in another language than English or Dutch, to assess eligibility for inclusion. We will screen reviews for the inclusion of data not published elsewhere and for references not found by our search strategy.
- Condition Being Studied
- As the use of gastric acid suppressants such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (HR2As) has increased, potential complications have also become more apparent. In adult literature, there is substantial evidence indicating an increased risk of community-acquired pneumonia (CAP) in patients using gastric acid suppressants. In view of this observation, careful consideration in prescribing these drugs is warranted, especially in patients at risk for community-acquired pneumonia, as is the case in children. Community-acquired pneumonia is a prevalent and serious childhood infection. In developing countries it remains one of the leading causes of death. Moreover, in high income countries it leads to increased morbidity, inpatient admission, economic burden, a decrease in quality of life and occasionally mortality. Given the increased and widespread use of PPIs and H2RAs in children it is important to attempt to further clarify the potential impact of gastric acid suppressant therapy on the risk of community-acquired pneumonia in the pediatric population. Our aim is to systematically review the available literature to determine the risk of community-acquired pneumonia in children using PPIs or H2RAs in the outpatient setting.
- Participant
- We will include studies investigating children aged 1 month until 18 years. Further, we will include studies describing both children and adults if data concerning children are reported separately.
- Animal
- Human Disease Modelled
- Intervention
- Interventions/exposure that will be examined are the use of proton pump inhibitors or histamine-2 receptor antagonists in the outpatient setting. We will exclude studies in which gastric acid suppressants are exclusively administered in the inpatient setting, intravenously, as part of Helicobacter pylori eradication therapy or peri-procedural.
- Comparator Control
- To assess the risk of community-acquired pneumonia in children using gastric acid PPI and H2RA the comparator of interest is no therapy. If possible, we also want to compare the incidence of community-acquired pneumonia in patients with PPI versus H2RA.
- Main Outcome
- The primary outcome of this systematic review is community-acquired pneumonia during outpatient treatment with proton pump inhibitors and histamine-2 receptor antagonists.
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Systematic review
- Keyword
- Child; Community-Acquired Infections; Histamine; Histamine H2 Antagonists; Humans; Pneumonia; Proton Pump Inhibitors; Risk
- Contact
- Linda van der Sande [email protected]
- Organisational Affiliation
- Maastricht University Medical Centre (MUMC)
- Funding Source
- Not applicable. For this project, there is no funding.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- Netherlands
- Review Stage
- Review Ongoing
- First Submission Date
- 2018-04-11
- Registration Date
- 2018-04-24
- Anticipated Start Date
- 2018-04-16
- Anticipated Completion Date
- 2018-09-03
- Title Cn
- 使用质子泵抑制剂或组胺-2受体拮抗剂的儿童患社区获得性肺炎的风险：系统评价
- Title En
- The risk of community-acquired pneumonia in children using proton pump inhibitors or histamine-2 receptor antagonists: a systematic review<br />
- Bilingual Status
- complete